The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
April 22, 2021
This publication discusses the use of Kyprolis (carfilzomib)— a proteasome inhibitor—for the treatment of myeloma.
April 21, 2021
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
November 30, 2018
This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
May 20, 2019
This publication discusses peripheral neuropathy, which can be a complication of multiple myeloma or its treatments.
May 18, 2018
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
We Thank Our Sponsors:
Amgen, GSK, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc. and Takeda